The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Steering Committee About Us Newsletter Contact
Visit:
AML Global Portal GVhD Hub MPN Hub Multiple Myeloma
Steering Committee About Us Newsletter Contact
Subtypes Therapeutics Congresses Trials Expert Opinions
SOHO 2020

When should patients with R/R NHL receive the bispecific antibody REGN1979?

Elina Simanovits
Joanna Nikitorowicz-Buniak
Rajat Bannerji
Dec 12, 2019
Share:

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Rajat Bannerji, Rutgers Cancer Institute of New Jersey, New Brunswick, US. We asked: Where might the bispecific antibody REGN1979 fit within the treatment pathway of patients with relapsed/refractory non-Hodgkin lymphoma?

Rajat Bannerji discussed the results of the dose-escalation stage of the first-in-human study phase I clinical trial. This CD20xCD3 antibody was well tolerated with no unexpected toxicities and early evidence of activity in follicular lymphoma, DLBCL, MZL and other.

When should patients with R/R NHL receive the bispecific antibody REGN1979?

Share:
More about...
Aggressive B-cell lymphomas ASH 2019 Diffuse large B-cell lymphoma Elina Simanovits Follicular lymphoma Indolent B-cell lymphomas Joanna Nikitorowicz-Buniak Marginal zone lymphoma Rajat Bannerji

Related articles

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month